latest update:
[TrialBase DB]

trial summary · NCT07227103

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

Trial record from the TrialBase DB dataset, status RECRUITING, condition Treatment Resistant Depression, sponsored by NeuroRx, Inc.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07227103phase PHASE2/PHASE3enrollment 240start 2026-12-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an alternative. Repetitive transcranial magnetic stimulation (rTMS) and more recently, theta-burst stimulation (TBS), are the noninvasive brain stimulation modalities with the largest evidence base in MDD. Although efficacious, an unacceptable proportion of patients do not significantly improve, and several aspects of the TMS parameter space are under investigation to enhance clinical outcomes. This study will compare Rapid Robotically-guided Transcranial Magnetic Stimulation (RRTMS) combined with an investigational neuroplasticity-inducing medication (NRX-101) to the effects of (1) sham TMS treatment and (2) placebo in achieving clinical response and remission from depression in patients with Treatment Resistant Depression. DCS has been shown in a randomized trial of more than double the percent response and remission from traditional TMS. When a one day (ONE-D) TMS protocol was combined with DCS, the measured response rate was 87% at one week. This trial will compare response and remission at six weeks following neuronavigated robotic-enabled Transcranial Magnetic Stimulation + NRX-101 (D-cycloserine/lurasidone) vs. TMS+placebo.

Source record: https://clinicaltrials.gov/study/NCT07227103

Facts

registry idNCT07227103
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2/PHASE3
study typeINTERVENTIONAL
lead conditionTreatment Resistant Depression
sponsorNeuroRx, Inc.
sponsor classINDUSTRY
enrollment240
start date2026-12-01
primary completion2027-12-31
completion2028-06-30
results postednot reported

Conditions

  • Treatment Resistant Depression
  • Treatment Resistant Depression (TRD)

Interventions

  • Neuronavigated robotic-enabled TMS
  • NRX-101
  • Sham TMS
  • Oral Placebo

Countries

  • United States

Intervention types: DEVICE, DRUG

Work with this record